Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. We base our approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. 

/Loxô/ is a term from Greek mythology that refers to the trajectory of an arrow, a fitting metaphor for our approach to developing precise, targeted therapies against genetically defined cancers.